MedTrace Logo

Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma

NCT01446497 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2011-10-05

No results posted yet for this study

Summary

Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic (Timolol) ophthalmic solutions in normal tension glaucoma patients.

Conditions

  • Normal Tension Glaucoma

Interventions

DRUG

Brimonidine/Timolol mixed combination

Twice per day, 1 drop at each time

DRUG

Timolol

Twice per day, 1 drop at each time

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Ki Ho Park, M.D, Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01446497 on ClinicalTrials.gov